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Background: The National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (NKF’s KDOQI) staging
system for chronic kidney disease (CKD) is based primarily on estimated GFR (eGFR). This study aimed at assessing
whether reclassification of subjects with type 2 diabetes using two recent classifications based on both eGFR and
albuminuria, the Alberta Kidney Disease Network (AKDN) and the Kidney Disease: Improving Global Outcomes
(KDIGO), provides a better definition of burden from cardiovascular disease (CVD) and diabetic retinopathy (DR)
than the NKF’s KDOQI classification.
Methods: This is a cross-sectional analysis of patients with type 2 diabetes (n = 15,773) from the Renal Insufficiency
And Cardiovascular Events Italian Multicenter Study, consecutively visiting 19 Diabetes Clinics throughout Italy in years
2007-2008. Exclusion criteria were dialysis or renal transplantation. CKD was defined based on eGFR, as calculated from
serum creatinine by the simplified Modification of Diet in Renal Disease Study equation, and albuminuria, as measured
by immunonephelometry or immunoturbidimetry. DR was assessed by dilated fundoscopy. Prevalent CVD, total and by
vascular bed, was assessed from medical history by recording previous documented major acute events.
Results: Though prevalence of complications increased with increasing CKD severity with all three classifications, it
differed significantly between NKF’s KDOQI stages and AKDN or KDIGO risk categories. The AKDN and KDIGO systems
resulted in appropriate reclassification of uncomplicated patients in the lowest risk categories and a more graded
independent association with CVD and DR than the NKF’s KDOQI classification. However, CVD, but not DR prevalence
was higher in the lowest risk categories of the new classifications than in the lowest stages of the NKF’s KDOQI, due to
the inclusion of subjects with reduced eGFR without albuminuria. CVD prevalence differed also among eGFR and
albuminuria categories grouped into AKDN and KDIGO risk category 1 and moderate, respectively, and to a lesser
extent into higher risk categories.
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Conclusions: Though the new systems perform better than the NKF’s KDOQI in grading complications and identifying
diabetic subjects without complications, they might underestimate CVD burden in patients assigned to lower risk
categories and should be tested in large prospective studies.
Trial registration: ClinicalTrials.gov; NCT00715481
Keywords: Chronic kidney disease, Classification, eGFR, Albuminuria, Cardiovascular disease, Diabetic retinopathyBackground
In 2002, the National Kidney Foundation’s Kidney Disease
Outcomes Quality Initiative (NKF’s KDOQI) has intro-
duced a staging system for chronic kidney disease (CKD)
[1]. Though widely used for both epidemiological and
clinical purposes, this 5-stage system has been criticized
for being based primarily on glomerular filtration rate
(GFR), as calculated by the use of equations which may
not provide accurate estimates, especially in elderly and
female individuals [2]. This may lead to erroneous
categorization of otherwise healthy individuals with
consequent overestimation of CKD prevalence and in-
appropriate referral to specialist [3]. In addition, the
NKF’s KDOQI classification does not entirely meet the
fundamental requirements for staging systems, which
should reflect the natural history and particularly the
prognosis of the disease.
That this system is often inadequate to describe the
sequence of events occurring in CKD has become in-
creasingly evident in view of the high prevalence of
nonalbuminuric renal impairment, i.e. estimated GFR
(eGFR) <60 ml/min/1.73 m2 without albuminuria, de-
tected in samples from the general population [4,5] and
also in patients with type 1 diabetes from the Diabetes
Control and Complications Trial (DCCT)/Epidemiology
of Diabetes Interventions and Complications study [6]
and, to a higher extent, in subjects with type 2 diabetes
from the United Kingdom Prospective Diabetes Study
[7]. This latter finding has been confirmed in large
cross-sectional analyses [5,8] and in the baseline evalu-
ation of two intervention trials [9,10], thus implying that
the majority of individuals with type 2 diabetes develop
CKD from stage 3 of the NFK’s KDOQI classification.
Therefore, the natural history of CKD in diabetes is now
recognized to follow two different pathways, albuminuric
and nonalbuminuric [11].
More importantly, the NKF’s KDOQI classification
was originally designed to assign people with more se-
vere prognoses to more advanced stages in order to se-
lect for referral only individuals at high risk for adverse
outcomes [1]. However, for definition of stages 3-5, this
classification does not incorporate information about the
presence and severity of albuminuria, which is a power-
ful predictor of renal and cardiovascular disease (CVD)outcomes, independently of eGFR, both in non-diabetic
and diabetic individuals [12-16]. The Kidney Disease:
Improving Global Outcomes (KDIGO) in a Controversies
Conference held in London in 2009 [17] recommended to
retain the NKF’s KDOQI definition of CKD and to revise
classification by including cause and albuminuria category
in addition to GFR category, with subdivision of GFR
category 3 at 45 ml/min/1.73 m2 (CGA classification).
Recently, an alternate classification system based on both
eGFR and albuminuria has been proposed and validated
by the Alberta Kidney Disease Network (AKDN) in terms
of adverse renal outcomes and, to a lesser extent, all-cause
mortality. In this classification, eGFR and albuminuria
categories with similar relative risks are grouped into
risk categories 1-4 (plus risk category 0 corresponding
to no CKD of the NKF’s KDOQI system) [18]. In the
accompanying editorial, Levey et al. did not recommend
substituting risk categories for eGFR and albuminuria
categories or relying on risk categories alone to predict
clinical outcomes [19]. However, in 2012, the KDIGO
has also grouped eGFR and albuminuria categories into
3 risk categories (moderate, high and very high risk,
plus low risk category also corresponding to no CKD of
the NKF’s KDOQI system) to be used for guiding deci-
sions and predicting outcomes [20]. So far, it has not been
investigated which CKD classification system stratifies
more accurately diabetic individuals by prevalence of CVD
and other complications.
This study was aimed at assessing whether reclassifi-
cation of subjects with type 2 diabetes from the Renal
Insufficiency and Cardiovascular Events (RIACE) Italian
Multicenter Study using the AKDN alternate system or
the new KDIGO classification provides a better defin-
ition of burden from CVD and diabetic retinopathy
(DR) than the NKF’s KDOQI classification.Methods
Study cohort
In this cross-sectional analysis, we used the data collected
at the baseline visit for the RIACE Italian Multicenter
Study, an observational, prospective cohort study on the
impact of eGFR on morbidity and mortality from CVD in
subjects with type 2 diabetes.
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patients with type 2 diabetes, attending consecutively 19
hospital-based Diabetes Clinics of the National Health
Service throughout Italy (see The RIACE Study Group)
in years 2007-2008. Exclusion criteria were dialysis or
renal transplantation. The study protocol was approved
by the locally appointed ethics committees. Then, quality
and completeness of data were controlled and 160 patients
were excluded due to implausible or missing values and
the remaining 15,773 subjects were subsequently analyzed.
Measurements
All patients underwent a structured interview to collect
the following information: age, smoking status, known
diabetes onset and duration, current glucose-, blood
pressure (BP)- and lipid-lowering therapy, with indication
of the class of drug. Weight and height were assessed and
body mass index (BMI) calculated, then BP was measured
with a sphygmomanometer after a 5-min rest. Hemoglobin
A1c (HbA1c) was measured by high-performance liquid
chromatography using DCCT-aligned methods; triglycer-
ides, total and HDL cholesterol were determined by stand-
ard analytical methods.
The presence of CKD was assessed by measuring
albuminuria and serum creatinine. As previously re-
ported in detail [8,21,22], albumin excretion rate was
obtained from 24-hour urine collections or calculated
from albumin/creatinine ratio in first-morning urine
samples, in the absence of symptoms and signs of urinary
tract infection or other interfering clinical conditions.
Albuminuria was measured in one-to-three fresh urine
samples for each patient by immunonephelometry or
immunoturbidimetry and, in case of multiple measure-
ments, the geometric mean was used for analysis. In
subjects with multiple measurements (4,062 with at
least two and 2,310 with three values), concordance rate
between the first value and the geometric mean was >90%
for all classes of albuminuria [21]. Patients were then
assigned to one of the following categories of albuminuria
(mg/24 hours): normoalbuminuria (<30), microalbumi-
nuria (30-299), or macroalbuminuria (≥300). Serum (and
urine) creatinine was measured by the modified Jaffe
method. One to three measurements were obtained for
each patients and eGFR was calculated by the four-
variable Modification of Diet in Renal Disease Study
equation [23], using the mean serum creatinine value in
case of multiple measures, as previously reported [8,21].
Patients were then assigned to one of the following cat-
egories of eGFR (mL/min/1.73 m2): 1 (≥90); 2 (60-89); 3
(30-59); 4 (15-29); and 5 (<15). All measurements were
undertaken from a standardized protocol across study
centers.
The presence of DR was assessed by an expert ophthal-
mologist with dilated fundoscopy. Patients were classifiedinto the following categories: absent DR, mild, moderate
or severe non-proliferative DR (NPDR), proliferative DR
(PDR), or maculopathy, according to the Global Diabetic
Retinopathy Project Group [24]. For further analysis,
patients with NPDR of mild or moderate degree were
classified as having non-advanced DR, whereas those with
severe NPDR or pre-PDR, PDR, maculopathy alone (i.e.
without NPDR or PDR), or blindness were grouped into
the advanced, sight-threatening DR category [25]. DR
grade was assigned based on the worst eye.
Prevalent CVD was assessed from medical history by
recording previous documented major acute CVD events,
including myocardial infarction, stroke, foot ulcer or gan-
grene, amputation, coronary, carotid, and lower limb
revascularization. CVD events were adjudicated based
on hospital discharge records by an ad hoc committee
in each center [26,27].Statistical analysis
Based on eGFR and albuminuria levels, patients were
stratified according to the NKF’s KDOQI, AKDN and
KDIGO classifications (Figure 1) in no CKD and stages
1-5, risk categories 0-4, and low, moderate, high and
very high risk, respectively.
Clinical data were then derived for subjects assigned to
each CKD stage or risk category, together with prevalence
of CVD and DR according to eGFR and albuminuria cat-
egories as well as CKD stages or risk categories. Differ-
ences among CKD stages or risk categories were evaluated
using the following statistical tests: one-way ANOVA
and Kruskall-Wallis for parametric and non-parametric
continuous variables, respectively, and Pearson χ2 for
categorical variables. A Mantel-Haenszel linear-by-linear
association χ2 test for linear trend was applied for evaluat-
ing variation of prevalence values with increasing eGFR
and albuminuria categories (i.e. from G0 to G5 and from
A1 to A3, respectively) as well as with increasing CKD
stage or risk category.
Multiple logistic regression analyses with backward
variable selection (probability for removal >0.10) were
performed to assess the relation of each complication with
CKD stages or risk categories as well as with subcategories
of AKDN risk categories 1, 2 and 3 and KDIGO risk cat-
egories moderate and high, independently of the following
confounders: age, gender, smoking habits, diabetes dur-
ation, HbA1c, anti-hyperglycemic treatment, triglycerides,
HDL cholesterol, dyslipidemia (elevated LDL cholesterol
and/or specific treatment), and hypertension (elevated
systolic and/or diastolic BP and/or specific treatment).
All p values were two-sided, and a p value of less than
0.05 was considered statistically significant. Statistical
analyses were performed using SPSS version 13.0 (SPSS
Inc., Chicago, Illinois, USA).
Figure 1 NFK’s KDOQI, AKDN risk category, and KDIGO CKD classification systems. NFK’s KDOQI classification: stage 0 (green), 1 (yellow), 2
(orange), 3 (red), 4 (brown), and 5 (blue); AKDN alternate system: risk category 0 (green), 1 (yellow), 2 (orange), 3 (red), and 4 (brown); KDIGO
classification: risk category low (green), moderate (yellow), high (orange), and very high (red).
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The clinical characteristics of subjects according to
NKF’s KDOQI stages and AKDN or KDIGO risk cat-
egories are presented in Additional file 1: Tables S1-S3.
Across all classification systems, age, age at diabetes
diagnosis, diabetes duration, HbA1c, percentage of insu-
lin users, triglycerides, non-HDL cholesterol, systolic BP,
prevalence of dyslipidemia, hypertension, lipid-lowering
therapy, and anti-hypertensive treatment (including usage
of blockers of the renin-angiotensin system), BMI, and
waist circumference tended to increase, whereas HDL
cholesterol and, except in the AKDN system, percentage
of current smokers decreased. Men predominated in
NKF’s KDOQI stages 1-2, whereas women prevailed in
stages 3-5, due to the higher percentage of females with
nonalbuminuric renal impairment, the most frequent
phenotype in subjects with eGFR < 60 ml/min/1.73 m2
[5,8]. Conversely, male gender predominated in all risk
categories of the AKDN and KDIGO classifications.
As previously reported [25,26], prevalence of any CVD
was 23.2% (any coronary event 15.3%, acute myocardial
infarction 11.2%, any cerebrovascular event 8.3%, stroke
3.3%, any peripheral event 5.7%, and ulcer/gangrene
3.4%) and that of any DR was 22.2% (non-advanced
12.4% and advanced 9.8%). Prevalence of CVD and DR
increased progressively with eGFR categories (P for
trend <0.0001), though coronary and cerebrovascular
events decreased in G4-G5 and G5, respectively, likelydue to a survival bias. Likewise, prevalence of all com-
plications showed a stepwise increase from normo to
macroalbuminuria (P for trend <0.0001) (Table 1).
Irrespective of the classification system, 62.5% of pa-
tients had no CKD and 37.5% had various degrees of
renal impairment, as previously detailed [8]: 18.8% had
albuminuria alone, and 18.7% had reduced eGFR, either
with (43.4%) or without (56.6%) albuminuria. However,
while the percentages of subjects with stages 1-2 and
stages 3-5 of the NKF’s KDOQI classification were al-
most identical, reclassification of nonalbuminuric patients
assigned to stages 3a (n = 1,253) and 3b (n = 351) and
microalbuminuric patients assigned to stage 2 (n = 1,653)
and 3a (n = 562) into risk category 1 or moderate and risk
category 2 or high with the AKDN and KDIGO systems,
respectively, resulted in a decreasing number of subjects
with increasing risk category, in keeping with the goal of
reducing referral for specialist care. Moreover, since
macroalbuminuric subjects with normal-to-high or mildly
reduced eGFR (n = 120 and n = 244, respectively; NKF’s
KDOQI stages 1-2) are classified into a higher risk cat-
egory with the AKDN alternate system (i.e. risk category
3) than with the KDIGO classification (i.e. high), the
number of patients decreased less strikingly from AKDN
risk category 2 to 3 than from the KDIGO risk category
high to very high (Figure 2).
Though prevalence of complications increased with in-
creasing CKD severity with all systems (P for trend <0.0001),
Table 1 Cases (% of total) and number of subjects (% of cases) with any CVD, any coronary event, AMI, any
cerebrovascular event, stroke, any peripheral event, ulcer/gangrene, and non-advanced and advanced DR according to
eGFR and albuminuria category
Cases Any CVD
N A1 A2 A3 Total n A1 A2 A3 Total
G1 3,610 (22.9) 932 (5.9) 120 (0.8) 4,662 (29.6) G1 539 (14.9) 197 (21.1) 35 (29.2) 771 (16.5)
G2 6,255 (39.7) 1,653 (10.5) 244 (1.6) 8,152 (51.7) G2 1,218 (19.5) 480 (29.0) 82 (33.6) 1,780 (21.8)
G3a 1,253 (7.9) 562 (3.6) 136 (0.9) 1,951 (12.4) G3a 373 (29.8) 220 (39.2) 67 (49.3) 660 (33.8)
G3b 351 (2.2) 263 (1.7) 136 (0.9) 750 (4.8) G3b 129 (36.8) 135 (51.3) 61 (44.9) 325 (43.3)
G4 60 (0.4) 82 (0.5) 87 (0.6) 229 (1.5) G4 24 (40.0) 40 (48.8) 56 (64.4) 120 (52.4)
G5 9 (0.06) 5 (0.03) 15 (0.1) 29 (0.2) G5 2 (22.2) 3 (60.0) 4 (26.7) 9 (31.0)
Total 11,538 (73.2) 3,497 (22.2) 738 (4.7) 15,773 (100.0) Total 2,285 (19.8) 1,075 (30.7) 305 (41.3) 3,665 (23.2)
Any coronary event AMI
N A1 A2 A3 Total n A1 A2 A3 Total
G1 369 (10.2) 122 (13.1) 17 (14.2) 508 (10.9) G1 260 (7.2) 86 (9.2) 11 (9.2) 357 (7.7)
G2 835 (13.4) 298 (18.0) 43 (17.6) 1,176 (14.4) G2 614 (9.8) 218 (13.2) 31 (12.7) 863 (10.6)
G3a 264 (21.1) 136 (24.2) 36 (26.5) 436 (22.4) G3a 189 (15.1) 105 (18.7) 22 (16.2) 316 (16.2)
G3b 93 (26.5) 96 (36.5) 39 (28.7) 228 (30.4) G3b 68 (19.4) 73 (27.8) 31 (22.8) 172 (22.9)
G4 16 (26.7) 23 (28.1) 23 (26.4) 62 (27.1) G4 13 (21.7) 18 (22.0) 15 (17.2) 46 (20.1)
G5 1 (11.1) 1 (20.0) 3 (20.0) 5 (17.2) G5 1 (11.1) 1 (20.0) 2 (13.3) 4 (13.8)
Total 1,578 (13.7) 676 (19.3) 161 (21.8) 2,415 (15.3) Total 1,145 (9.9) 501 (14.3) 112 (15.2) 1,758 (11.2)
Any cerebrovascular event Stroke
N A1 A2 A3 Total n A1 A2 A3 Total
G1 167 (4.6) 62 (6.7) 12 (10.0) 241 (5.2) G1 57 (1.6) 23 (2.5) 7 (5.8) 87 (1.9)
G2 403 (6.4) 194 (11.7) 30 (12.3) 627 (7.7) G2 169 (2.7) 80 (4.8) 13 (5.3) 262 (3.2)
G3a 136 (10.9) 89 (15.8) 33 (24.3) 258 (13.2) G3a 52 (4.2) 28 (5.0) 13 (9.6) 93 (4.8)
G3b 48 (13.7) 53 (20.2) 23 (16.9) 124 (16.5) G3b 20 (5.7) 22 (8.4) 8 (5.9) 50 (6.7)
G4 11 (18.3) 19 (23.2) 22 (25.3) 52 (22.7) G4 3 (5.0) 8 (9.8) 10 (11.5) 21 (9.2)
G5 0 (0.0) 2 (40.0) 1 (6.7) 3 (10.3) G5 0 (0.0) 2 (40.0) 0 (0.0) 2 (6.9)
Total 765 (6.6) 419 (12.0) 121 (16.4) 1,305 (8.3) Total 301 (2.6) 163 (4.7) 51 (6.9) 515 (3.3)
Any peripheral event Ulcer/gangrene
N A1 A2 A3 Total n A1 A2 A3 Total
G1 99 (2.7) 51 (5.5) 11 (9.2) 161 (3.5) G1 53 (1.5) 38 (4.1) 9 (7.5) 100 (2.2)
G2 247 (4.0) 133 (8.1) 29 (11.9) 409 (5.0) G2 130 (2.1) 80 (4.8) 23 (9.4) 233 (2.9)
G3a 102 (8.1) 68 (12.1) 25 (18.4) 195 (10.0) G3a 53 (4.2) 42 (7.5) 17 (12.5) 112 (5.7)
G3b 23 (6.6) 48 (18.3) 24 (17.7) 95 (12.7) G3b 16 (4.6) 33 (12.6) 13 (9.6) 62 (8.3)
G4 3 (5.0) 8 (9.8) 19 (21.8) 30 (13.1) G4 2 (3.3) 6 (7.3) 13 (14.9) 21 (9.2)
G5 1 (11.1) 2 (40.0) 2 (13.3) 5 (17.2) G5 1 (11.1) 2 (40.0) 1 (6.7) 4 (13.8)
Total 475 (4.1) 310 (8.9) 110 (14.9) 895 (5.7) Total 255 (2.2) 201 (5.8) 76 (10.3) 532 (3.4)
Non-advanced DR Advanced DR
N A1 A2 A3 Total n A1 A2 A3 Total
G1 389 (10.8) 131 (14.1) 16 (13.3) 536 (11.5) G1 212 (5.9) 127 (13.6) 21 (17.5) 360 (7.7)
G2 657 (10.5) 258 (15.6) 37 (15.2) 952 (11.7) G2 425 (6.8) 229 (13.9) 63 (25.8) 717 (8.8)
G3a 165 (13.2) 105 (18.7) 30 (22.1) 300 (15.4) G3a 120 (9.6) 91 (16.2) 40 (29.4) 251 (12.9)
G3b 43 (12.3) 50 (19.0) 30 (22.1) 123 (16.4) G3b 47 (13.4) 56 (21.3) 35 (25.7) 138 (18.4)
G4 10 (16.7) 12 (14.6) 18 (20.7) 40 (17.5) G4 8 (13.3) 19 (23.2) 39 (44.8) 66 (28.8)
G5 0 (0.0) 1 (20.0) 5 (33.3) 6 (20.7) G5 0 (0.0) 1 (20.0) 7 (46.7) 8 (27.6)
Total 1,264 (11.0) 557 (15.9) 136 (18.4) 1,957 (12.4) Total 812 (7.0) 523 (15.0) 205 (27.8) 1,540 (9.8)
CVD, cardiovascular disease; AMI, acute myocardial infarction; DR, diabetic retinopathy; eGFR, estimated glomerular filtration rate.eGFR (ml/min/1.73 m2):
G1 = ≥90; G2 = 60-89; G3a = 45-59; G3b = 30-44; G4 = 15-29; G5 = <15; albuminuria: A1 =mormoalbuminuria; A2 =microalbuminuria; A3 =macroalbuminuria.
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AKDN or KDIGO risk categories (Figures 2 and 3). In fact,
since prevalence of CVD, but not DR, was higher in patients
with nonalbuminuric renal impairment (NKF’s KDOQI
stages 3-5) than in micro and macroalbuminuric sub-
jects with normal-to-high or mildly reduced eGFR
(NKF’s KDOQI stages 1-2) (Table 1) [8,25], prevalence of
any CVD, any coronary events, and myocardial infarction
was significantly higher in risk category 1 or moderate
than in stage 1 (P at least <0.001) as well as in risk
category 2 (P < 0.0001) or high (P at least <0.005) than in
stage 2, whereas prevalence of advanced DR was higher in
risk category 3 or very high than in stage 3 (P < 0.0001).
Moreover, since CVD prevalence was relatively low in
macroalbuminuric subjects with non-reduced eGFR
(included in AKDN and KDIGO risk category 3 and high,
respectively) [8], it tended to plateau between AKDN risk
categories 2 and 3, whereas they increased markedly from
KDIGO risk category high to very high (Figures 2 and 3).Figure 2 Cases (% of total, A) and prevalence (% of cases, number of su
and advanced (D) DR according to CKD NFK’s KDOQI stage (left), AKDN
classification: stage 0 (green), 1 (yellow), 2 (orange), 3 (red), 4 (brown), and 5 (b
(orange), 3 (red), and 4 (brown); KDIGO classification: risk category low (green)However, a higher number of subjects without CVD
(2,788) or DR (2,808) were appropriately classified in the
lowest risk categories of the new systems (i.e. 1 and mod-
erate, respectively) than in NKF’s KDOQI stage 1 (820 and
757, respectively). Logistic regression analysis showed
that the strength of association of complications, in-
dependent of confounders, increased more progres-
sively with AKDN and particularly KDIGO risk
categories than with NKF’s KDOQI stages, except for
cerebrovascular and peripheral events. In addition,
NKF’s KDOQI stage 1 was not significantly associated
with any CVD event and CVD events by vascular
bed, except ulcer/gangrene, whereas stage 2 did not
correlate with any CVD and coronary events. Finally, the
odd ratios for CVD, except cerebrovascular events, tended
to plateau between AKDN risk categories 3 and 4 or even
2 and 4 (Figure 4).
Likewise, significant differences were detected when
prevalence of complications in eGFR and albuminuriabjects on top of columns) of any CVD (B) and non-advanced (C)
risk category (middle), and KDIGO risk category (right). NFK’s KDOQI
lue); AKDN alternate system: risk category 0 (green), 1 (yellow), 2
, moderate (yellow), high (orange), and very high (red).
Figure 3 Prevalence (% of cases, number of subjects on top of columns) of any coronary event (A), AMI (B), any cerebrovascular event (C),
stroke (D), any peripheral event (E), and ulcer/gangrene (F) according to CKD NFK’s KDOQI stage (left), AKDN risk category (middle), and
KDIGO risk category (right). NFK’s KDOQI classification: stage 0 (green), 1 (yellow), 2 (orange), 3 (red), 4 (brown), and 5 (blue); AKDN alternate system:
risk category 0 (green), 1 (yellow), 2 (orange), 3 (red), and 4 (brown); KDIGO classification: risk category low (green), moderate (yellow), high (orange),
and very high (red).
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category were compared. As previously reported [8],
prevalence of CVD was higher in normoalbuminuric sub-
jects with mildly reduced than in those with normal-to-
high eGFR (no CKD with the NKF’s KDOQI classification,
corresponding to risk categories 0 and low with the new
systems, P = 0.03 to <0.0001) and that of CVD and DR
in individuals with reduced eGFR and albuminuria than
in those without albuminuria (NKF’s KDOQI CKD stages
3-5, P = 0.002 to <0.0001) (Table 1). Moreover, logistic re-
gression analysis showed that, within AKDN risk category
1 and the corresponding KDIGO risk category moderate,
the independent relation of CVD events, except stroke
and ulcer/gangrene, was 1.5-to-2.0-fold higher with
G3a-A1 (normoalbuminuric subjects with eGFR 45-
59 ml/min/1.73 m2) and 1.2-to-1.7-fold higher with G2-
A2 (microalbuminuric subjects with eGFR 60-89 ml/min/
1.73 m2) than with G1-A2 (microalbuminuric subjectsFigure 4 Independent* relation of any CVD, any coronary event, AMI
gangrene, and non-advanced and advanced DR with CKD NKF’s KDOQ
age, gender, smoking habits, diabetes duration, HbA1c, anti-hyperglycemic tre
The green lines indicate the reference categories (i.e. no CKD stage, risk ca
classifications, respectively). * P<0.0001.with eGFR ≥90 ml/min/1.73 m2) categories (Table 2), con-
sistent with the finding that prevalence of CVD is higher
in nonalbuminuric stages 3-5 than in stages 1-2 [8]. Con-
versely, the strength of correlation of advanced DR was
lower with G3a-A1 than with G2-A2 and G1-A2 categor-
ies (Table 2), in keeping with the weaker association of this
complication with reduced eGFR than with albuminuria
[25]. Less striking were differences among eGFR and albu-
minuria categories grouped into AKDN risk categories 2
and 3 and KDIGO risk category high (not shown).
Discussion
In this cross-sectional analysis of the RIACE study, we
compared three CKD classification systems regarding their
ability to define CVD and DR burden. As reported in the
general population [18,20,28], the percentage of patients
assigned to more advanced stages or risk categories de-
creased markedly when individuals staged with the NKF’, any cerebrovascular event, stroke, any peripheral event, ulcer/
I stages, and AKDN and KDIGO risk categories. * Confounders:
atment, triglycerides, HDL cholesterol, dyslipidemia, and hypertension.
tegory 0 and risk category low for NKF’s KDOQI, AKDN, and KDIGO
Table 2 Independent* relation of any CVD, any coronary event, AMI, any cerebrovascular event, stroke, any peripheral
event, ulcer/gangrene, and non-advanced and advanced DR with eGFR and albuminuria categories grouped into AKDN
risk category 1 and the corresponding KDIGO risk category moderate
eGFR and albuminuria category G1-A2 G2-A2 G3a-A1
Complication OR OR (95 % CI) P OR (95 % CI) P
Any CVD 1.0 1.273 (1.038-1.562) 0.020 1.595 (1.264-2.012) <0.0001
Any coronary event 1.0 1.293 (1.011 1.653) 0.040 1.883 (1.431 2.477) <0.0001
AMI 1.0 1.294 (0.974-1.718) 0.075 1.907 (1.390-2.614) <0.0001
Any cerebrovascular event 1.0 1.483 (1.080-2.036) 0.015 1.641 (1.147-2.349) 0.007
Stroke 1.0 1.708 (1.048-2.783) 0.032 1.587 (0.916-2.748) 0.099
Any peripheral event 1.0 1.409 (0.988 2.009) 0.058 2.005 (1.359 2.959) <0.0001
Ulcer/gangrene – – – – –
Non-advanced DR 1.0 0.994 (0.779-1.267) 0.961 0.771 (0.584 1.017) 0.065
Advanced DR 1.0 1.020 (0.784-1.328) 0.883 0.647 (0.474 0.884) 0.006
*Confounders: age, gender, smoking habits, diabetes duration, HbA1c, anti-hyperglycemic treatment, triglycerides, HDL cholesterol, dyslipidemia, and hypertension.
CVD, cardiovascular disease; AMI, acute myocardial infarction; DR, diabetic retinopathy; eGFR, estimated glomerular filtration rate; KDIGO, kidney disease: improving
global outcomes; OR, odd ratio; CI, confidence interval.
G1-A2: eGFR ≥90 ml/min/1.73 m2 with microalbuminuria (reference category); G2-A2: eGFR 60-89 ml/min/1.73 m2 with microalbuminuria; G3a-A1: eGFR 45-59 ml/
min/1.73 m2 with normoalbuminuria.
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reclassified with the AKDN (7.34% assigned to risk cat-
egory ≥3) and particularly the KDIGO (5.03% assigned to
risk category very high) systems. This implies that, accord-
ing to the rationale of the new classifications [18,20], a
lower number of subjects with type 2 diabetes would be
referred for specialist care, with significant cost savings. It
remains to be clarified whether reclassification also im-
proves accuracy of referral in terms of better prediction of
morbidity and mortality in diabetic individuals.
Previous studies in the general population using the
AKDN alternate system have shown that it better pre-
dicts adverse renal outcomes and all-cause mortality [18],
whereas the NKF’ KDOQI classification is superior for
identifying CKD complications such as anemia, acidosis,
hyperphosphatemia, hyperparathyroidism and hypertension
(but not hypoalbuminemia) [28]. However, reclassification
with the alternate system was less accurate for mortality
than for the renal outcome, since it consistently and in-
correctly reclassified more patients who died to a lower
category [18], whereas it more likely assigned to lower
stages patients without each CKD complication [28], as
compared the NKF’ KDOQI classification.
Our study focused on CVD and DR, the main compli-
cations of diabetes which affect more frequently diabetic
patients with CKD than those without [25,29], and pro-
foundly impact on life expectancy and quality of these
individuals [30,31].
Results showed that prevalence of complications differed
significantly between NKF’s KDOQI stages and AKDN or
KDIGO risk categories and also among eGFR and albu-
minuria categories grouped into the same risk category.
As expected, a large number of subjects without CVD andDR were correctly reclassified in the lowest risk category
of the new systems. Moreover, the AKDN and particularly
the KDIGO classification showed a more graded associ-
ation with CVD and DR than the NKF’s KDOQI staging
system, independently of confounders, thus supporting
the concept that the new systems provide a better defin-
ition of CVD and DR burden in type 2 diabetes, consistent
with previous data on renal outcomes and all-cause mortal-
ity from the general population [18]. Under the assumption
that subjects assigned to the lowest risk category would not
be referred for specialist care, at variance with those classi-
fied as AKDN risk categories ≥2 or KDIGO risk catego-
ries ≥ high, this would result in more accurate and less
expensive management of diabetic individuals with CKD.
However, CVD, but not DR prevalence was higher in
risk category 1 or moderate than in stage 1 (except ulcer/
gangrene) as well as in risk category 2 or high than in stage
2, consistent with previous data comparing the AKDN al-
ternate system with the NKF’s KDOQI classification in the
NHANES cohort [28]. In addition, prevalence differed also
among eGFR and albuminuria categories grouped into
AKDN and KDIGO risk category 1 and moderate, respect-
ively, and to a lesser extent into higher risk categories of
the new systems. Both findings are attributable to the rela-
tively high prevalence of CVD in individuals with nonalbu-
minuric renal impairment, higher than that in subjects
with albuminuria and normal-to-high or mildly reduced
eGFR [8], especially for coronary events [26]. This might
imply that assignment of individuals with type 2 diabetes
and normoalbuminuria who fall into eGFR category 3a
and 3b to risk categories 1 (or moderate) and 2 (or high),
respectively, should be tested in large prospective studies
and eventually reconsidered with classification of these
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up of the RIACE Study will provide insight into this issue.
Strengths of this study include the large size of the
cohort, the completeness of data and the analysis of a
contemporary dataset. The main limitation is the cross-
sectional design of the study. Potential limitations concern-
ing assessment of CKD and DR, including non-centralized
measurements of albuminuria and serum creatinine and the
use of funduscopy have been addressed in previous RIACE
reports [8,21,25]. Briefly, as an external quality control of
urinary albumin assays, 50 samples from each center were
re-analyzed at the reference laboratory of the Coordinating
center, confirming that the coefficient of variations between
the peripheral and the central values were <15%, at least in
the relevant clinical range of 15-500 mg/L [8,21]. Moreover,
fundus was examined by an expert an ophthalmologist in
each center, who was asked to fill in a standardized report
format for classifying the RIACE participants [25].
In conclusions, the new AKDN and KDIGO systems
seem to perform better than the NKF’s KDOQI classifica-
tion in grading CVD and DR burden in subjects with type
2 diabetes. However, though these systems reclassify up-
ward a large proportion of patients without complications,
thus reducing unnecessary referrals, they appear to under-
estimate the burden from CVD, but not DR in diabetic sub-
jects assigned to lower risk categories, especially those with
reduced eGFR without albuminuria (see Additional file 1:
Table S4). This suggests that the new systems should be
tested for CVD and DR outcomes in prospective studies,
in order to improve risk stratification of diabetic individ-
uals with CKD.
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